- Home
- SISI vs CERO Comparison
SISI vs CERO Comparison
Compare SISI & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- CERO
- Stock Information
- Founded
- SISI 1997
- CERO 2017
- Country
- SISI China
- CERO United States
- Employees
- SISI N/A
- CERO N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- CERO
- Sector
- SISI Health Care
- CERO
- Exchange
- SISI Nasdaq
- CERO Nasdaq
- Market Cap
- SISI 5.6M
- CERO 6.1M
- IPO Year
- SISI 2016
- CERO N/A
- Fundamental
- Price
- SISI $5.60
- CERO $5.39
- Analyst Decision
- SISI
- CERO Strong Buy
- Analyst Count
- SISI 0
- CERO 2
- Target Price
- SISI N/A
- CERO $45.00
- AVG Volume (30 Days)
- SISI 97.6K
- CERO 82.8K
- Earning Date
- SISI 11-13-2025
- CERO 11-18-2025
- Dividend Yield
- SISI N/A
- CERO N/A
- EPS Growth
- SISI N/A
- CERO N/A
- EPS
- SISI N/A
- CERO N/A
- Revenue
- SISI $9,601,324.00
- CERO N/A
- Revenue This Year
- SISI N/A
- CERO N/A
- Revenue Next Year
- SISI N/A
- CERO N/A
- P/E Ratio
- SISI N/A
- CERO N/A
- Revenue Growth
- SISI 1133.26
- CERO N/A
- 52 Week Low
- SISI $1.00
- CERO $4.27
- 52 Week High
- SISI $271.50
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- SISI 43.37
- CERO 40.84
- Support Level
- SISI $5.42
- CERO $5.18
- Resistance Level
- SISI $6.27
- CERO $5.45
- Average True Range (ATR)
- SISI 0.61
- CERO 0.24
- MACD
- SISI -0.04
- CERO 0.09
- Stochastic Oscillator
- SISI 12.49
- CERO 56.96
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.